The British pharmaceutical company AstraZeneca returned to growth in the third quarter thanks to a strong new pharmaceutical company. The company was also confident in the coming years and expects an ongoing recovery. Product revenue rose 8% to $ 5.26 billion in the third quarter due to the strong demand for new cancer drugs. Chief Executive Officer Pascal Soriot spoke on Thursday for an important day for AstraZeneca and the beginning of a period of continuous growth in the coming years. For the full year, it expects to increase product sales by a low single digit rate at fixed exchange rates and by 9% in a stable currency in the third quarter.
In recent years, AstraZeneca suffered massively from the loss of patents for older drugs from her home, losing more than half of its sales. Carriers of hope are now ten new drugs, which last grew by 85%. Tailwind also comes from businesses in China, the second-largest drug market in the world, where revenue in the third quarter grew by nearly one-third. Despite the positive news from the product side, the group is still in transition. Total revenue declined by 14% to $ 5.34 billion in the last quarter, and adjusted operating earnings declined by 29% to $ 1.3 billion.